Trial Profile
A Phase I, Open-label, Dose-escalating Study of the Safety or Percutaneous Intra-tumoral Injection of TG4023 (MVA-FCU1) Combined With Systemic Administration of 5-fluorocytosine in Patients With Primary or Secondary Hepatic Tumors
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 26 Oct 2016
Price :
$35
*
At a glance
- Drugs TG 4023 (Primary) ; Flucytosine
- Indications Liver cancer
- Focus Adverse reactions; First in man; Proof of concept
- Sponsors Transgene
- 29 Sep 2016 Results (n=16) assessing feasibility and tolerability of TG4023 published in the Annals of Oncology (2016).
- 18 Sep 2009 New trial record